[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335090-105":59,"doc-detail-335090-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","lineage-specific-canonical-and-non-canonical-activity-of-ezh2-in-advanced-prostate-cancer-subtypes","Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes","","Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase and therapeutic target overexpressed in castration-resistant prostate cancers. The study defines lineage-specific and differential EZH2 activity across prostate adenocarcinoma and neuroendocrine prostate cancer (NEPC) subtypes to clarify how EZH2 controls differentiation and lineage plasticity, and to identify mediators of response and resistance to EZH2 inhibitors. Mechanistically, EZH2 regulates bivalent genes, upregulating NEPC transcriptional drivers such as ASCL1, supporting forward differentiation after EZH2 targeting and suggesting cyclin/CDK co-targeting to overcome resistance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/lineage-specific-canonical-and-non-canonical-activity-of-ezh2-in-advanced-prostate-cancer-subtypes/335090/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/lineage-specific-canonical-and-non-canonical-activity-of-ezh2-in-advanced-prostate-cancer-subtypes/335090.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is EZH2’s role in advanced prostate cancer according to the article?","Question",{"text":112,"@type":113},"EZH2 is described as a histone methyltransferase overexpressed in most castration-resistant prostate cancers and implicated in driving disease progression and resistance to hormonal therapies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does EZH2 activity differ between prostate adenocarcinoma and NEPC subtypes?",{"text":117,"@type":113},"The article defines lineage-specific EZH2 actions in both subtypes, linking EZH2 activity to differentiation and lineage plasticity. It reports that EZH2 modulates bivalent genes and contributes to NEPC-associated transcriptional programs, such as ASCL1.",{"name":119,"@type":110,"acceptedAnswer":120},"What therapeutic rationale does the study suggest for overcoming resistance to EZH2 inhibition?",{"text":121,"@type":113},"Subtype-specific effects of EZH2 inhibition on cell cycle genes are used to support co-targeting cyclin/CDK pathways as a potential strategy to overcome resistance to EZH2 inhibitors.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335090,1791361872,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article [https://doi.org/10.1038/s41467-024-51156-5](https://doi.org/10.1038/s41467-024-51156-5)  \nLineage-speciﬁc canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes  \nReceived: 19 February 2024  \n\n| Accepted: 31 July 2024 |\n| --- |\n| |\n| Check for updates |\n\nVaradha Balaji Venkadakrishnan 1,2,3, Adam G. Presser1, Richa Singh4, Matthew A. Booker5, Nicole A. Traphagen1, Kenny Weng 1,6,  \nNathaniel C. E. Voss1,7, Navin R. Mahadevan1,8, Kei Mizuno1, Loredana Puca9, Osasenaga Idahor1,12, Sheng-Yu Ku 1,2,3, Martin K. Bakht 1,2,3,  \nAshir A. Borah 3,13,14, Zachary T. Herbert10, Michael Y. Tolstorukov 5, David A. Barbie1, David S. Rickman 4, Myles Brown 1,11 &  \nHimisha Beltran 1,2,3   \nEnhancer of zeste homolog 2 (EZH2) is a histone methyltransferase and emerging therapeutic target that is overexpressed in most castration-resistant prostate cancers and implicated as a driver of disease progression and resistance to hormonal therapies. Here we deﬁne the lineage-speciﬁc action and differential activity of EZH2 in both prostate adenocarcinoma and neuroendocrine prostate cancer (NEPC) subtypes of advanced prostate cancer to better understand the role of EZH2 in modulating differentiation, lineage plasticity, and to identify mediators of response and resistance to EZH2 inhibitor therapy. Mechanistically, EZH2 modulates bivalent genes that results in upregulation of NEPC-associated transcriptional drivers (e.g., ASCL1) and neuronal gene programs in NEPC, and leads to forward differentiation after targeting EZH2 in NEPC. Subtype-speciﬁc downstream effects of EZH2 inhibition on cell cycle genes support the potential rationale for co-targeting cyclin/ CDK to overcome resistance to EZH2 inhibition.  \nLineage plasticity is a mechanism of treatment resistance seen across many cancer types1. In prostate cancer, lineage plasticity is associated with resistance to hormonal therapies which can manifest clinically asahistologic transformation from prostate adenocarcinoma (PRAD) toneuroendocrine prostate cancer (NEPC)2. Lineage plasticity occurs in up to 15-20% of late-stage prostate cancers and is associated with poor prognosis3,4. Expression of androgen receptor (AR), the main driver of PRAD, is often lost in NEPC along with other luminal prostate features5.  \nEpigenetic dysregulation is a major driver of cancer lineage plasticity6,7. We reported that NEPC arises clonally from PRAD with shared genomic features8, acquiring distinct changes in DNA methylation and chromatin accessibility that are associated with dysregulation of lineagedetermining transcription factors that distinguish NEPC from PRAD8–11. Epigenetic de-repression of cell fate commitment transcription factors likely facilitates lineage plasticity and NEPC progression12. The polycomb repressive complex (PRC2) regulates the epigenetic mark  \n1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 2Harvard Medical School, Boston, MA, USA. 3The Broad Institute of MIT and Harvard, Cambridge, MA, USA. 4Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA. 5Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, MA, USA. 6Boston College, Chestnut Hill, MA, USA. 7Belmont Hill School, Belmont, MA, USA.  \n8Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA. 9Department of Medicine, Weill Cornell Medicine, New York, NY, USA. 10Molecular Biology Core Facilities, Dana-Farber Cancer Institute, Boston, MA, USA. 11Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA. 12Present address: Harvard University, Cambridge, MA, USA. 13Present address: Department of Urology, University of California at San Francisco, San Francisco, CA, USA. 14Present address: Arc Institute, Palo Alto, CA, USA. e-mail: [himisha_beltran@dfci.harvard.edu](himisha_beltran@dfci.harvard.edu)  \nH3K27me3 associated with transcriptional repression13, and this function","cbCairf881tWVJLv","https://ap.wps.com/l/cbCairf881tWVJLv","pdf",2964576,15,"English","# Introduction\n## Lineage plasticity and prostate cancer subtype switching\n## Epigenetic dysregulation and PRC2/EZH2 roles\n# Results\n## NEPC preclinical models show modest response to EZH2 inhibitor therapy","[{\"question\":\"What is EZH2’s role in advanced prostate cancer according to the article?\",\"answer\":\"EZH2 is described as a histone methyltransferase overexpressed in most castration-resistant prostate cancers and implicated in driving disease progression and resistance to hormonal therapies.\"},{\"question\":\"How does EZH2 activity differ between prostate adenocarcinoma and NEPC subtypes?\",\"answer\":\"The article defines lineage-specific EZH2 actions in both subtypes, linking EZH2 activity to differentiation and lineage plasticity. It reports that EZH2 modulates bivalent genes and contributes to NEPC-associated transcriptional programs, such as ASCL1.\"},{\"question\":\"What therapeutic rationale does the study suggest for overcoming resistance to EZH2 inhibition?\",\"answer\":\"Subtype-specific effects of EZH2 inhibition on cell cycle genes are used to support co-targeting cyclin/CDK pathways as a potential strategy to overcome resistance to EZH2 inhibitors.\"}]","Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes | PDF",1790009626,38]